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features and predict response to adjuvant therapy in breast cancer.
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ABSTRACT  
Uracil in DNA is an important cause of mutagenesis. SMUG1 is a uracil DNA glycosylase that 
removes uracil through base excision repair. SMUG1 also processes radiation induced oxidative 
base damage as well as 5-fluorouracil incorporated into DNA during chemotherapy. We 
investigated SMUG1 mRNA expression in 249 primary breast cancers. SMUG1 protein expression 
was investigated in 1165 breast tumours randomised into two cohorts [training set (n=583) and test 
set (n= 582)]. SMUG1 and chemotherapy response was also investigated in a series of 315 ER 
negative tumours (n=315).  For mechanistic insights, SMUG1 was correlated to biomarkers of 
aggressive phenotype, DNA repair, cell cycle and apoptosis. Low SMUG1 mRNA expression was 
associated with adverse disease specific survival (p=0.008) and disease free survival (p=0.008). 
Low SMUG1 protein expression (25%) was associated with high histological grade (p<0.0001), 
high mitotic index (p<0.0001), pleomorphism (p<0.0001), glandular de-differentiation (p=0.0001), 
absence of hormonal receptors (ER-/PgR-/AR) (p<0.0001), presence of basal-like (p<0.0001) and 
triple negative phenotypes (p<0.0001).  Low SMUG1 protein expression was associated with loss 
of BRCA1 (p<0.0001), ATM (p<0.0001) and XRCC1 (p<0.0001). Low p27 (p<0.0001), low p21 
(p=0.023), mutant p53 (p=0.037), low MDM2 (p<0.0001), low MDM4 (p=0.004), low Bcl-2 
(p=0.001), low Bax (p=0.003) and high MIB1 (p<0.0001) were likely in low SMUG1 tumours.  
Low SMUG1 protein expression was associated with poor prognosis in univariate (p<0.001) and 
multivariate analysis (p<0.01). In ER+ cohort that received adjuvant endocrine therapy, low 
SMUG1 protein expression remains associated with poor survival (p<0.01). In ER- cohort that 
received adjuvant chemotherapy, low SMUG1 protein expression is associated with improved 
survival (p=0.043). Our study suggests that low SMUG1 expression may correlate to adverse 
clinicopathological features and predict response to adjuvant therapy in breast cancer. 
 
Key words: DNA Base Excision Repair; SMUG1; breast cancer; prognostic factor; predictive 
factor. 
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INTRODUCTION  
 
Uracil in DNA is an important cause of mutagenesis and may result either from incorporation of 
dUMP during replication leading to U:A mismatches,  spontaneous generation or by enzymatic 
deamination of cytosine leading to U:G mismatches. Unrepaired U:G mismatches are 100% 
mutagenic leading to G:C to A:T transition mutations that are frequently seen in human tumours 
[1]. Uracil DNA repair is essential to protect against mutagenicity and this is accomplished by the 
DNA base excision repair (BER) machinery. Uracil BER is initiated by uracil DNA glycosylases. 
UNG2 and SMUG1 are important uracil DNA glycosylases that process uracil in DNA [1].  
 
Emerging data suggests a role for SMUG1 in carcinogenesis. Smug1 was shown to be an important 
uracil-DNA glycosylase in Ung-deficient mice [2]. In Msh2(-/-) mice, loss of Smug1 as well as Ung 
increases cancer predisposition [3]. In addition, a 10-fold increase in spontaneous C:G to T:A 
transitions has been observed in cells deficient in Smug1 and Ung [4]. Smug1 and Ung deficient 
cells were also hypersensitive to ionizing radiation in that study [4]. A recent study has also 
demonstrated that in premenopausal women, SMUG1 rs2029166 genotype may increase breast 
cancer risk in those with low folate intake [5].   
 
SMUG1 as well as UNG may also be essential for excising 5-fluorouracil (5-FU) incorporated into 
the DNA during chemotherapy. Although Smug1 knockdown was shown to result in accumulation 
of 5-FU [6], the study however, did not take into consideration possible differences in growth rate 
or pool perturbation of nucleotide pool sizes. In a recent study, loss of UNG did not affect 5-FU 
sensitivity but loss of SMUG1 led to two fold increase in sensitivity to 24h treatment of 5-FU 
followed by recovery. In cell exposed to continuous 5-FU, however, no difference was observed in 
Smug1 depleted cells. Upon 5-FU treatment, SMUG1-depleted cells did show a prolonged S-phase 
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arrest and a transient increase in DNA double-strand breaks in that study [7]. Similarly, the role of 
Ung in 5-FU sensitivity has also been described in cell lines [8, 9]. SMUG1 is also a key enzyme 
for repairing 5-hydroxymethyluracil, 5-formyluracil, 5,6-dihydrouracil, alloxan and other lesions 
generated during oxidative base damage induced by ionising radiation and oxygen free radicals [4]. 
Removal of uracil in BER creates an abasic site (AP site) which is processed further by several 
enzymes including human AP endonuclease (APE1), poly (ADP-ribose) polymerase 1 (PARP1), 
DNA polymerase  and DNA ligase III-XRCC1 heterodimer which completes the repair process 
[10]. A recent study has also suggested a role for smug1 in RNA metabolism [11] implying 
additional functions for SMUG1.   
 
Given the emerging role of SMUG1 in the maintenance of genomic integrity, we hypothesised that 
SMUG1 may be dysregulated in breast cancer. In the current study, we have investigated SMUG1 
mRNA and protein expression in primary operable breast cancers and have demonstrated for the 
first time that SMUG1 deficiency may be linked to aggressive clinical phenotype and also predicts 
response to therapy.  
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MATERIALS AND METHODS 
 
Study population 
Uppsala cohort for SMUG1 mRNA expression: The Uppsala cohort originally composed of 315 
women representing 65% of all breast cancers resected in Uppsala County, Sweden, from January 
1, 1987, to December 31, 1989. Demographics are summarized in supplementary Table S1 of 
supporting information and also described elsewhere [12]. Tumour samples were microarray 
profiled on the Affymetrix U133A&B genechips. Microarray analysis was carried out at the 
Genome Institute of Singapore. All microarray data are accessible at National Center for 
Biotechnology Information (NCBI) Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/). 
Data can be accessed via series accession number (GSE4922). RNA preparation, microarray 
hybridization, and data processing were carried out essentially as described [13]. All data were 
normalized using the global mean method (MAS5), and probe set signal intensities were natural log 
transformed and scaled by adjusting the mean signal to a target value of log 500. 
Nottingham cohort for SMUG1 protein expression: The study was performed in a consecutive 
series of patients with primary invasive breast carcinomas who were diagnosed between 1986 and 
1999 and entered into the Nottingham Tenovus Primary Breast Carcinoma series. A series of 1165 
primary operable breast cancers were available. Patients were randomised into two equal cohorts by 
use of a double random number sort.  Alternate cases were put into a training set (583 tumours) and 
a test set (583 tumours). All patients were treated uniformly in a single institution and have been 
investigated in a wide range of biomarker studies [14-16].   Supplemental Table S2 summarizes 
patient demographics. Both cohorts were well balanced with regards to clinicopathological features, 
treatment and survival data. Patients received standard surgery (mastectomy or wide local excision) 
with radiotherapy.  Prior to 1989, patients did not receive systemic adjuvant treatment (AT). After 
1989, AT was scheduled based on prognostic and predictive factor status, including Nottingham 
Prognostic Index (NPI), oestrogen receptor-α (ER-α) status, and menopausal status. Patients with 
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NPI scores of <3.4 (low risk) did not receive AT. Pre-menopausal patients with NPI scores of ≥3.4 
(high risk) were given classical Cyclophosphamide, Methotrexate, and 5-Flourouracil (CMF) 
chemotherapy; patients with ER-α positive tumours were also offered hormone therapy (HT). 
Postmenopausal patients with NPI scores of ≥3.4 and ER-α positivity were offered HT, while ER-α 
negative patients received classical CMF chemotherapy. Median follow up was 111 months (range 
1 to 233 months).  Survival data, including overall survival, disease-free survival (DFS), and 
development of loco-regional and distant metastases (DM), was maintained on a prospective basis.  
DFS was defined as the number of months from diagnosis to the occurrence of local recurrence, 
local lymph node (LN) relapse or DM relapse.  Breast cancer specific survival (BCSS) was defined 
as the number of months from diagnosis to the occurrence of BC related-death. Local recurrence-
free survival (LRS) was defined the number of months from diagnosis to the occurrence of local 
recurrence. DM-free survival was defined as the number of months from diagnosis to the 
occurrence of DM relapse.  Survival was censored if the patient was still alive at the time of 
analysis, lost to follow-up, or died from other causes. 
We also evaluated a cohort of 315 ER-α negative invasive BCs. Demographic and treatment 
characteristics of this cohort are summarised in supplementary Table S3.  
The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria, 
recommended by McShane et al [17], were followed throughout this study. This work was approved 
by Nottingham Research Ethics Committee. 
Tissue Microarrays (TMAs) and immunohistochemistry (IHC) 
Tumours were arrayed in tissue microarrays (TMAs) constructed with 2 replicate 0.6mm cores from 
the centre and periphery of the tumours. The TMAs were immunohistochemically profiled for 
SMUG1 and other biological antibodies [ER, PR, AR, Her-2,  CK5/6, CK14, EGFR, ATM, 
BRCA1, XRCC1, P27, P21, MIB1, Bax, BCL-2, p 53, MDM2 and MDM4 as previously described 
[18-21] (primary antibodies, clone, source, optimal dilution and scoring system used for each 
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immunohistochemical marker is summarized in supplementary Table S4)]. Immunohistochemical 
staining for SMUG1 was performed using the Bond Max automated staining machine and Leica 
Bond Refine Detection kit (DS9800) according to manufacturer instructions (Leica Microsystems).  
TMAs sections were incubated for 15 minutes at room temperature with 1/200 goat anti-SMUG1 
monoclonal antibody (Acris Antibody GmbH).  Pre-treatment of TMA section was performed with 
citrate buffer (pH 6.0) for 20 minutes.  HER2 expression was assessed according to the new 
ASCO/CAP guidelines using IHC and fluorescence in situ hybridisation (FISH) [22].  
Evaluation of immune staining: We utilised H-score method as well as quick score method for 
SMUG1 nuclear staining analysis in tumours.  For H-score assessment, whole field inspection of 
the core was performed and intensities of nuclear staining were grouped as follows: 0 = no staining, 
1 = weak staining, 2 = moderate staining, 3 = strong staining. The percentage of staining in each 
category was estimated (0-100%).  H-score (range 0-300) was calculated by multiplying intensity of 
staining by percentage staining as previously described [18-21].  Low SMUG1 (SMUG1-) 
expression was defined by mean H-score ≤35.     
For quick-score, the intensity and proportion of cells staining for SMUG1 was analysed. Proportion 
of staining was scored as follows: 0 (negative), 1 (≤1%), 2 (1-10%), 3 (11-33%), 4 (34-66%) and 5 
(>66-100%). Intensity of staining was scored as follows: 1 (weak), 2 (moderate) and 3 (strong). The 
two scores were added to give a quick-score in the range 0-8 (by definition, there is no quick-score 
of 1) [19]. Low SMUG1 (SMUG1-) expression was defined by Quick score < 4 which was 
equivalent to H-score ≤35. Not all cores within the TMA were suitable for IHC analysis due to 
missing cores or absence of tumour cells. 
Cancer cell lines and culture: In addition to the breast cancer cell lines (MCF-7, MDA-MB-231, 
MDA-MB-436), we also investigated colon cancer cell lines (Colo-205, C-170), gastric cancer cell 
lines (AGS, ST-16) and pancreatic cancer cell lines (Panc1, ASPC-1) for SMUG1 protein 
expression.  The cell lines were purchased from ATCC and grown in RPMI medium supplemented 
with 10% FBS, 1% penicillin/streptomycin. 
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Western blot analysis: This assay was performed as described previously [23]. Primary antibodies 
used was an anti-SMUG1 goat polyclonal antibody (catalogue no: AP08884PU-N, Acris Antibody 
GmbH, Germany). The secondary antibody was a HRP conjugated secondary anti-goat (Dako, 
Glostrup, Denmark) antibody. As well as cell extracts from the cell lines, recombinant GST-tagged 
SMUG1 protein (Novus biological, USA)  was simultaneously used as a positive control and to 
investigate the specificity of anti-SMUG1 antibody .   
Statistical analysis: Data analysis was performed using SPSS (SPSS, version 17 Chicago, IL). 
Where appropriate, Pearson’s Chi-square, Fisher’s exact, Student’s t and ANOVA one-way tests 
were used. Cumulative survival probabilities were estimated using the Kaplan–Meier method, and 
differences between survival rates were tested for significance using the log-rank test. Multivariate 
analysis for survival was performed using the Cox proportional hazard model. The proportional 
hazards assumption was tested using standard log-log plots. Hazard ratio (HR) and 95% confidence 
intervals (95% CI) were estimated for each variable. All tests were two-sided with a 95% CI and a p 
value < 0.05 considered significant.  For multiple comparisons, p values were adjusted according to 
Holm-Bonferroni correction method [24].  
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RESULTS 
 
Low SMUG1 transcript levels correlate to poor survival  
We first evaluated SMUG1 mRNA expression in 249 breast cancers comprising the Uppsala cohort. 
50.6% of tumours had high SMUG1 mRNA levels and 49.4% of tumours had low SMUG1 mRNA 
expression levels. Low SMUG1 mRNA expression in tumours was associated with adverse disease 
specific survival (p=0.008) (Figure 1A) and disease free survival (p=0.008) (Figure 1B) in patients. 
We then proceeded to investigate SMUG1 protein expression in breast cancer. 
Low SMUG1 protein expression is linked to aggressive phenotype  
We evaluated specificity of SMUG1 antibody by western blot analysis. In addition to the breast 
cancer cell lines (MCF-7, MDA-MB-231, MDA-MB-436), we also investigated colon cancer cell 
lines (Colo-205, C-170), gastric cancer cell lines (AGS, ST-16) and pancreatic cancer cell lines 
(Panc1, ASPC-1) for SMUG1 protein expression.  Recombinant SMUG1 protein was used as a 
positive control. Figure 2A demonstrates robust SMUG1 protein expression across a panel of cancer 
cell lines. The anti-SMUG1 antibody that specifically binds recombinant SMUG1 protein was used 
as a positive control and provides evidence for the specificity of the antibody. In addition, Figure 
2B demonstrates more than two-fold reduction in SMUG1 expression in MDA-MB-436 cells 
compared to MCF-7 cells providing evidence of differential expression of SMUG1 across breast 
cancer cell lines. We then proceeded to conduct immunohistochemical (IHC) evaluation of SMUG1 
protein expression in human breast cancers. We first investigated in a training set and then validated 
in a test set of breast cancer cohorts. 
a) Training set (n=583):145/583 (25%) of the tumours were low for SMUG1 expression, and 
439/583 (75%) tumours were high for SMUG1 expression (Figure 2E and 2F). Low SMUG1 
expression was highly significantly associated with adverse pathological features (Table 1) 
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including high histological grade (p<0.0001), high mitotic index (p<0.0001), pleomorphism 
(p<0.0001) and glandular de-differentiation (p=0.0001). In addition, low SMUG1 expression was 
significantly linked to aggressive phenotypic features such as absence of hormonal receptors (ER-
/PgR-/AR) (p<0.0001), EGFR over expression (p=0.024), presence of basal like phenotype 
(p<0.0001) and triple negative phenotype (p<0.0001) (Table 1).   
Low SMUG1 expression was significantly associated with loss of expression of BRCA1 
(p<0.0001), ATM (p<0.0001) and XRCC1 (p<0.0001).  Loss of p27 and p21 expression was more 
common in low SMUG1 tumours (p<0.0001 and p=0.023 respectively). High MIB1 was 
significantly associated with low SMUG1 expression (p<0.0001).  Low SMUG1 expression was 
also significantly associated with low expression of p53 downstream genes that regulate cell cycle 
progression and apoptosis such as MDM2 (p=0.016), MDM4 (p=0.0003), Bcl2 (p<0.0001) and Bax 
(p=0.008).   
In the full cohort, low SMUG1 expression is associated with adverse clinical outcome at 10 years, 
with a significant increase in the risk of death (p<0.0001) (Figure 2G) and recurrence (p=0.005) 
(Figure 2H)  compared with high SMUG1 tumours.  Low SMUG1 ER + breast cancers receiving 
adjuvant endocrine therapy had poor survival (p=0.023) and a trend to increased recurrence 
(p=0.099) compared to patients with high SMUG1 tumours (Figures 3A and 3B).  
In multivariate Cox regression analysis including other validated prognostic factors (such as lymph 
node stage, histological grade and tumour size), low SMUG1 was an independent predictor for 
breast cancer specific survival (p= 0.018) as well as disease free survival (p=0.031) (Table 3).  
b) Test set (n= 582): 138/582 (24%) of the tumours were low for SMUG1 expression, and 444/582 
(76%) tumours were high for SMUG1 expression. Low SMUG1 expression was highly 
significantly associated with adverse pathological features (Table 1) including larger tumours 
(p=0.009), high histological grade (p<0.0001), high mitotic index (p<0.0001), pleomorphism 
(p<0.0001) and glandular de-differentiation (p=0.0042). In addition, low SMUG1 expression was 
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also significantly linked to aggressive features such as absence of hormonal receptors (ER-/PgR-
/AR) (p<0.0001), EGFR over expression (p=0.002), HER-2 overexpression (p=0.038), presence of 
basal like phenotype (p<0.0001) and triple negative phenotype (p<0.0001) (Table 1).   
Low SMUG1 expression was significantly associated with loss of expression of BRCA1 (p=0.01), 
ATM (p=0.002) and XRCC1 (p<0.0001).  Loss of p27 was more common in low SMUG1 tumours 
(p<0.0001). High MIB1 was significantly associated with low SMUG1 tumours (p<0.0001).  Low 
SMUG1 expression was also significantly associated with mutant p53 (p=0.037) as well as low 
expression of p53 downstream genes that regulate cell cycle progression and apoptosis such as 
MDM2 (p<0.0001), MDM4 (p=0.004), Bcl2 (p=0.001) and Bax (p=0.003).   
In the full cohort, low SMUG1 expression is associated with adverse clinical outcomes at 10 years 
with a significant increase in the risk of death (p<0.0001) (Figure 2I) and recurrence (p=0.006) 
(Figure 2J) compared with SMUG1 high tumours.  Low SMUG1 ER+ breast cancers receiving 
adjuvant endocrine therapy had poor survival (p=0.003) and increased recurrence (p=0.016) 
compared to patients with SMUG1 high tumours (Figures 3C and 3D).  
In multivariate Cox regression analysis including other validated prognostic factors (such as lymph 
node stage, histological grade and tumour size), low SMUG1 expression was an independent 
predictor for breast cancer specific survival (p= 0.027) as well as disease free survival (p=0.034) 
(Table 3).  
Clinicopathological significance in ER negative breast cancers (n= 315) 
 
77/315 (24%) of the tumours were low for SMUG1 expression, and 238/315 (76%) tumours were 
high for SMUG1 expression. Low SMUG1 expression was significantly associated with high 
vascular invasion (p=0.01) and triple negative phenotype (p=0.003) (Table 4). Her-2 over 
expression (p=0.001) and lymph node positive disease (p=0.008) was more likely in SMUG1 high 
tumours. Low SMUG1 expression was more likely to be associated with XRCC1 loss in this cohort. 
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In ER- patients who received chemotherapy, high SMUG1 expression was associated with 2-fold 
increase in risk of death (p=0.043) and recurrence (p=0.043) indicating resistance to chemotherapy 
(Figures 3E and 3F). 
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DISCUSSION 
 
Impaired DNA repair may increase mutation rate, enhance chromosomal instability and promote 
selection of more malignant clones with aggressive behaviour [25, 26]. SMUG1 uracil DNA 
glycosylase may be an anti-mutator protein involved in BER [2]. Besides a role in genomic 
integrity, a recent study has also suggested a critical role for smug1 in RNA metabolism [11].  This 
is the first study to evaluate SMUG1 expression in breast cancer. We provide the first evidence that 
low SMUG1 expression in breast tumours is associated with an aggressive phenotype such as high 
histological grade, pleomorphism, glandular de-differentiation, absence of hormonal receptors and 
presence of basal like and triple negative phenotypes. Low SMUG1 expression is also associated 
with loss of expression of BRCA1, ATM and XRCC1, implying genomic instability in SMUG1 low 
tumours. Moreover, association with abnormal expression of p53, p27, MDM2, MDM4, Bcl-2 and 
Bax provides additional evidence for higher level of genomic instability in SMUG1 low tumours. 
Low SMUG1 expression was associated with poor survival in univariate as well as multivariate 
analysis in both the training and test set that predominantly consisted of ER + tumours (80%). In 
ER+ tumours that received endocrine therapy, in particular, low SMUG1 expression is also 
associated with poor survival indicating that SMUG1 status may predict endocrine response, 
although the mechanism for resistance is unknown. On the other hand, in ER- tumours that received 
chemotherapy, low SMUG1 expression is associated with better survival indicating sensitivity to 
chemotherapy. The clinical data presented in ER- tumours is consistent with preclinical studies 
where SMUG1 depletion has been shown to result in sensitivity to 5-FU chemotherapy [6, 27].   
 
In a recent study in 112 gastric cancers, we found that SMUG1 high tumours were associated with 
adverse clinical outcome such as poor disease free survival (p=0.02) and disease specific survival 
(p=0.05) [28].  The data in gastric cancer is in contrast to that presented in breast tumours in the 
current study. We speculate that low SMUG1 expression in breast cancer may increase genomic 
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instability and promote a cancerous phenotype. On the other hand, in gastric cancer, where 
inflammation is driver for carcinogenesis, up-regulation of BER may be required to repair oxidative 
base damage that is commonly seen in an inflammatory environment. SMUG1 up-regulation in this 
context could promote cancer survival and resistance to therapy. Taken together, the data suggests 
that SMUG1 may have complex roles in carcinogenesis and larger studies in multiple tumour types 
are required to clarify further the role of SMUG1 in cancer. A limitation to our study is that it is 
retrospective. Although we have demonstrated that low SMUG1 is associated with an aggressive 
phenotype, we have not directly shown that SMUG1 loss results in a mutator phenotype in breast 
cancer.  Aggressive tumours are highly proliferative and it is possible that SMUG1 down-regulation 
in highly proliferative tissue may have no causal relation to the aggressive phenotype. Future 
mechanistic preclinical studies could clarify whether SMUG1 loss confers a mutator phenotype in 
breast cancer.  
The link between DNA repair,  ER, p53 and its downstream targets MDM2 and  p21 in breast 
cancer are beginning to emerge  [29]. Although the regulation of uracil DNA glycosylases is largely 
unknown, recent studies suggest a potential role for p53.  For example, thymine DNA glycosylase 
(TDG) that belongs to the superfamily of uracil DNA glycosylases, has been shown to be 
transcriptionally regulated by p53 [30]. Moreover,  PPM1D, a p53-induced oncogenic phosphatase 
has been shown to interact with uracil DNA glycosylase (UNG2) and suppress BER [31]. 
Interestingly, p73, a member of p53 family, may be directly involved in transcriptional regulation of 
SMUG1 [32]. Whether p53 is also involved in SMUG1 regulation remains unknown.  In addition, 
NFI/CTF transcription factor has also been shown to be involved in SMUG1 regulation [33] 
implying that SMUG1 regulation may be complex in cells. 
We recently investigated XRCC1, another key BER protein in breast cancer [23]. As seen in 
SMUG1, loss of XRCC1 (16%) was also associated with high grade (p<0.0001), loss of hormone 
receptors (p<0.0001), triple negative (p<0.0001) and basal like phenotypes (p=0.001). Loss of 
XRCC1 was associated with a 2-fold increase in risk of death (p<0.0001) and independently with 
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poor outcome (p<0.0001). We also demonstrated a novel synthetic lethality application using DNA 
double strand break repair inhibitors in XRCC1 deficient breast cancer cells [23]. Taken together, 
our data suggests that BER deficiency in breast tumours contribute to aggressive clinical behaviour 
and could be targeted for personalized treatment strategy in patients.  
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Table 1. Association between SMUG expression and clinicopathologic variables in the training set 
Variable                                                                                  SMUG1 expression 
                                                                                             Low                         High                Adjusted p value 
 A) Pathological    Parameters 
 
Tumour Size    0.043 
T1 a + b (≤1.0) 9 (6.3) 53 (12.2)  
T1 c (>1.0 -2.0) 67 (46.9) 219 (50.5)  
T2 (>2.0-5) 63 (44.1) 158 (36.4)  
T3 (>5) 4 (2.8) 4 (0.9)  
Lymph node stage    0.223 
Negative 81 (56.6) 266 (61.1)  
Positive (1-3 nodes) 52 (36.4) 127 (29.2)  
Positive (>3 nodes) 10 (7) 42 (9.7)  
Grade**   <1 x 10
- 6 
G1 15 (10.5) 78 (18)  
G2 23 (16.1) 180 (41.5)  
G3 105 (73.4) 176 (40.6)  
Tumour Types   0.003 
IDC-NST 88 (72.7) 214 (54.2)  
Tubular 16 (13.2) 90 (22.8)  
ILC 5 (4.1) 10 (2.5)  
Medullary 5 (4.1) 10 (2.5)  
Others 7 (5.8) 39 (9.9)  
Mitotic Index   1 x 10 
-6 
M1 (low; mitoses < 10) 20 (14.4) 180 (41.6)  
M2 (medium; mitoses 10-18)  23 (16.5) 97 (22.4)  
M3 (high; mitosis >18) 96 (69.1) 156 (36)  
Pleomorphism    
1 (small-regular uniform) 1 (0.7) 15 (3.5) 1 x 10 
-6
 
2 (Moderate variation) 33 (23.7) 199 (46)  
3 (Marked variation) 105 (75.5) 219 (50.6)  
Tubule formation   1.8 x 10 
-3 
1 (>75% of definite tubule) 2 (1.4) 31 (7.2)  
2 (10%-75% definite tubule) 38 (27.3) 159 (36.7)  
3 (<10% definite tubule) 99 (71.2) 243 (56.1)  
B) Aggressive phenotype 
 
   
EGFR expression   0.024 
Low 78 (72.9) 289 (82.8)  
High 29 (27.1) 60 (17.2)  
Her2 overexpression    0.502 
No 121 (87.7) 384 (89.7)  
Yes 17 (12.3) 44 (10.3)  
Triple negative    1 x 10 
- 6 
No    89 (64) 372  
Yes 50 (36) 53 (12.5)  
Basal phenotype          7 x 10 
-5 
No                       95 (76) 378 (89.8)  
Yes 30 (24) 43 (10.2)  
C) Hormone receptors 
 
   
ER   < 1 x 10
-6
 
Negative 66 (46.5) 84 (19.8)  
Positive 76 (53.5) 341 (80.2)  
PgR    6.9 x 10 
-5 
Negative     76 (56.7) 150 (37.1)  
Positive 58 (43.3) 254 (62.9)  
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AR      9.5 x 10
 -5 
Negative 55 (50) 104 (29.7)  
Positive 55 (50) 246 (70.3)  
D)DNA Repair 
 
   
ATM expression   2.6 x 10 
-4 
Negative 67 (69.8) 128 ( 48.1)  
Positive 29 (30.2) 138 (51.9)  
BRCA 1 expression   1 x 10 
- 6 
Negative 44 (45.8) 41 (13.1)  
Positive 52 (54.2) 271 (86.9)  
XRCC1 expression   < 1 x 10 
-6 
Low 46 (36.3) 30 (8.6)  
High 71 (60.7) 319 (91.4)  
E) Cell cycle/apoptosis regulators 
 
   
p27 expression   8 x 10 
-4 
Low 76 (80.9) 180 (59.6)  
High 18 (19.1) 121 (40.1)  
p21 expression   0.023 
Negative 68 (63) 174 (50.4)  
Positive 40 (37) 171 (49.6)  
MIB1   <1 x 10 
-6 
Low 21 (17.9) 155 (42.8)  
High 96 (82.1) 207 (57.2)  
Bcl-2 expression    < 1 x 10 
-6 
No 63 (51.2) 98 (24.6)  
Yes         60 (48.8) 301 (75.4)  
Bax expression   0.008 
Low 76 (82.6) 188 (68.1)  
High 16 (17.4) 88 (31.9)  
P53 expression    0.123 
Low                        86 (76.1) 295 (82.6)  
High 27 (23.9) 62 (17.4)  
MDM2 expression   0.016 
Low 87 (85.3) 241 (73.7)  
High 15 (14.7) 86 (26.3)  
MDM4 expression   3.2 x 10 
-3 
Low 88 (93.6) 240 (80.8)  
High 6 (6.4) 57 (19.2)  
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Table 2. Association between SMUG1 expression and clinicopathologic variables in the test set 
Variable                                                                        SMUG1 expression 
                                                                                     Low                        High                           Adjusted p value 
                                                                                     N(%)                     N(%) 
 
A) Pathological    Parameters 
Tumour Size    0.009 
T1 a + b (≤1.0) 13 (9.4) 52 (11.8)  
T1 c (>1.0 -2.0) 65 (47.1) 224 (50.9)  
T2 (>2.0-5) 51 (37) 158 (35.9)  
T3 (>5) 9 (6.5) 6 (1.4)  
Lymph node stage    0.223 
Negative 81 (56.6) 266 (61.1)  
Positive (1-3 nodes) 52 (36.4) 127 (29.2)  
Positive (>3 nodes) 15 (10.9) 36 (8.2)  
Grade**   < 1 X 10 
-6 
G1 15 (10.5) 78 (18)  
G2 23 (16.1) 180 (41.5)  
G3 105 (73.4) 176 (40.6)  
Tumour Types   0.045 
IDC-NST 82 (69.5) 220 (55.1)  
Tubular 17 (14.4) 91 (22.8)  
ILC 9 (7.6) 50 (12.5)  
Medullary 4 (3.4) 8 (2)  
Others 6 (5.1) 30 (7.5)  
Mitotic Index   2 X 10 
-6 
M1 (low; mitoses < 10) 26 (19) 180 (41)  
M2 (medium; mitoses 10-18)  24 (17.5) 80 (41)  
M3 (high; mitosis >18) 87 (63.5) 179 (40.8)  
Pleomorphism   1 X 10 
-6 
1 (small-regular uniform) 1 (0.7) 11 (2.5)  
2 (Moderate variation) 28 (0.4) 193 (44.1)  
3 (Marked variation) 108 (78.8) 234 (53.4)  
Tubule formation   0.042 
1 (>75% of definite tubule) 3 (2.2) 30 (6.8)  
2 (10%-75% definite tubule) 39 (28.5) 147 (33.5)  
3 (<10% definite tubule) 95 (69.3) 262 (59.7)  
B) Aggressive phenotype    
EGFR expression   0.002 
Low 84 (75) 313 (87.2)  
High 28 (25) 46 (12.8)  
Her2 overexpression    0.038 
No 116 (84.1) 396 (90.4)  
Yes 22 (15.9) 42 (9.6)  
Triple negative    4.9 x 10 
-6 
No    96 (07.1) 365 (85.5)  
Yes 41 (29.9) 62 (14.5)  
Basal phenotype          3.2 X 10 
-4 
No                       109 (81.3) 391 (92.2)  
Yes 25 (18.7) 33 (7.8)  
C) Hormonal receptors    
ER   3 x 10 
-6 
Negative 58 (42) 94 (21.7)  
Positive 80 (58) 339 (78.3)  
PgR    5 x 10
 -6 
Negative     77 (57.5 ) 145 (35.2)  
Positive 57 (42.5) 267 (64.8)  
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AR      
                
3.2 X 10 
-4 
Negative 57 (52.3) 121 (33.2)  
Positive 52 (47.7) 243 (66.8)  
D) DNA Repair    
ATM expression   0.002 
Negative 55 (66.3) 117 (46.4)  
Positive 28 (33.7) 135 (53.6)  
BRCA 1 expression   0.01 
Negative 29 (27.9) 54 (16.4)  
Positive 75 (72.1) 275 (83.6)  
XRCC1 expression   < 1 x 10 
-6 
Low 34 (31.5) 39 (10.9)  
High 74 (68.5) 320 (89.1)  
E) Cell cycle/apoptosis regulators    
p27 expression   4.5 x 10 
-5 
Low 78 (80.4) 154 (54.8)  
High 19 (19.6 ) 126 (44.8)  
p21 expression   0.212 
Negative 64 (64) 195 (57)  
Positive 36 (36) 147 (43)  
MIB1   7.8 x 10 
5 
Low 22 (19) 145 (38.9)  
High 94 (81) 228 (61.1)  
Bcl-2 expression    0.001 
Low 63 (50) 142 (34.1)  
High         63 (50) 275 (65.9)  
Bax expression   0.003 
Low 77 (81.9) 188 (65.5)  
High 17 (18.1) 99 (34.5)  
P53 expression    0.037 
Low                        80 (72.1) 315 (81.2)  
High 31 (27.9) 73 (18.8)  
MDM2 expression   5 X 10 
-6 
Low 97 (94.2) 233 (72.8)  
High 6 (5.8) 87 (27.2)  
MDM4 expression   0.004 
Low 91 (93.8) 239 (81.8)  
High 6 (6.2) 53 (18.2)  
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Table  3. Multivariate Cox regression analysis of both training and test sets 
Variables BCSS at 10 years DFS at 10 years 
Training  Set Test  Set Training  Set Test Set 
HR CI 95% p HR CI 5% p HR CI 95% p HR CI 95% p 
Low SMUG1 1.5 1.08-2.20 0.018* 1.5 1.05-2.06 0.027* 1.4 1.03-1.91 0.031* 1.3 1.03-1.83 0.034* 
Lymph node stage  
Negative 
Positive (1-3 
nodes)  
Positive (>3 nodes) 
 
1 
1.8 
2.8 
 
 
1.25-2.54 
1.71-4.64 
0.00005*  
1 
1.2 
4.1 
 
 
0.84-1.78 
2.65-6.31 
5.7x10
-10*  
1 
1.4 
2.2 
 
 
1.02-1.88 
1.37-3.43 
0.002*  
1 
1.2 
3.6 
 
 
0.91-1.65 
2.48-5.27 
1.2x10
-10* 
Grade** 
G1 
G2 
G3 
 
1 
1.5 
2.5 
 
 
0.74-2.87 
1.32-4.73 
0.001*  
 
2.5 
7.0 
 
1 
1.04-6.10 
3.04-15.9 
2.0x10
-9*
  
1 
0.8 
1.2 
 
1 
0.53-1.30 
0.78-1.83 
0.085  
1 
1.4 
1.8 
 
1 
0.90-2.16 
1.17-2.69 
0.018* 
Size (continuous) 1.3 1.12-1.49 0.0005* 1.1 1.01-1.24 0.038* 1.2 1.05-1.37 0.006* 1.1 1.04-1.25 007
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Table 4: Association between SMUG1 expression and clinicopathological variables in ER negative cohort 
 
 
Variable SMUG1 expression Adjusted 
 p value Low (n= 77)               High (n=  238)                       
    0.424 
T1 a + b (≤1.0) 5 (6.8) 27 (11.6)  
T1 c (>1.0 -2.0) 30 (41.1) 101(43.5)  
T2 (>2.0-5) 35 (47.9) 90 (38.8)  
T3 (>5) 3 (4.1) 14 (6)  
Grade**   0.257 
G1 
G2 
0 
5 (6.5) 
0 
26 (10.9) 
 
G3 72 (93.5) 212 (89.1)  
Lymph node metastasis   0.008* 
No 60 (77.9) 146 (61.3)  
Yes 17 (22.1) 92 (38.7)  
Mitotic Index   0.028** 
M1 (low; mitoses < 10) 3 (3.9) 17 (7.2)  
M2 (medium; mitoses 10-18) 7 (9.2) 50 (21.1)  
M3 (high; mitosis >18) 66 (86.8) 170 (71.7)  
Lympho-vascular invasion   0.01* 
No 13 (17.1) 77 (32.5)  
Yes 63 (82.9) 160 (67.5)  
Pleomorphism 
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
0 
76 (100) 
33 (45.8) 
 
3 (1.3) 
234 (98.7) 
106 (49.3) 
0.324 
Tubule formation   0.672 
1 (>75% of definite tubule) 0 1 (0.4)  
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
8 (10.5) 
68 (89.5) 
32 (13.5) 
204 (86.1) 
 
Her2 overexpression   0.001* 
No 72 (93.5) 177 (75.6)  
Yes 5 (6.5) 57 (24.4)  
Triple negative   0.003* 
No 7 (9.1) 58 (24.8)  
Yes 70 (90.9) 176 (75.2)  
ATM expression   0.712 
Negative 40 (64.5) 117 (61.9)  
Positive 22 (35.5) 72 (38.1)  
BRCA 1 expression   
 
Negative 59 (88.1) 186 (92.1) 0.317 
Positive 8 (11.9) 16 (7.9)  
XRCC1 expression   
 
Low 19 (26.4) 29 (12.6) 0.005* 
High 53 (73.6) 202 (87.4)  
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FIGURE LEGENDS 
Figure 1: SMUG1 mRNA expression in breast cancer. A. Kaplan Meier curves showing 
breast cancer specific survival (BCSS). B.  Disease free survival (DFS) in the training set (C) 
Figure 2: SMUG1 protein expression in breast cancer. A. Western blot of recombinant 
SMUG1 protein and cell extract from a panel of cancer cell lines (see text for details). B. 
Western blot demonstrating more than two-fold reduction in SMUG1 expression in MDA-
MB-436 cells compared to MCF-7 cells. C.  Microphotograph of SMUG1 high and low 
breast cancer tissue.  Kaplan Meier curves showing breast cancer specific survival (BCSS) in 
the training set (D), disease free survival (DFS) in the training set (E), breast cancer specific 
survival (BCSS) in the test set (F) and disease free survival (DFS) in the test set (G). See text 
for details. 
Figure 3: SMUG1 protein expression in breast cancer.  Kaplan Meier curves showing breast 
cancer specific survival (BCSS) in ER + tumours that received endocrine therapy (training 
set) (A), disease free survival (DFS) in ER + tumours that received endocrine therapy 
(training set) (B), breast cancer specific survival (BCSS) in ER + tumours that received 
endocrine therapy (test set) (C), disease free survival (DFS) in ER + tumours that received 
endocrine therapy (test set)  (D), breast cancer specific survival (BCSS) in ER - tumours that 
received chemotherapy (E), disease free survival (DFS) in ER - tumours that received 
chemotherapy (F). See text for details. 
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